Keytruda (pembrolizumab)

pCPA File Number: 23013
Negotiation Status:
Concluded with an LOI
Indication(s):
As monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors
Sponsor/Manufacturer:
Merck Canada Inc.
CDA-AMC Project Number:
PC0377-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: